RE: Book so strong, 10P+ inbound9 Sep 2025 08:49
1. No big pharma will leave such a disruptive potential drug in the hand of another competitor and a fierce bid will soon be unleashed because time is of the essence. This drug will eat up a big chunk of their business as it makes many of their profitable drugs redundant. Therefore irrespective of the patent or even the phase 3 result, they will seek ownership of IMM if only to keep it on lead, or even the bottom drawer will serve them well. In a market of £100 billions, paying £1 billion+ even if you don’t use it makes a business sense for the pharmaceutical companies. For them to then develop it to commercialisation, would be just a bonus, and an extremely lucrative one. So whichever you look at it, IMM will be taken over and very soon, no need to wait for the granting of the patent or phase 3 result, as otherwise you’ll be beaten the next pharma. Tim makes it clear he’s been talking several potential suitors and even corrected the Sunday Roast guy to say he is expecting a deal this quarter. And another “surprise” deal for the same period for the other IMM products. So news for either can land anytime. Having come to this conclusion, I’ve plunged in big time relative to my normal investment strategy. GLA